USA

CMR Surgical will continue to develop its products and manage commercialisation in markets outside the US.

Under the agreement, Labcorp will pay US$722 million in cash upfront for BioReference’s clinical and women’s health testing businesses, urology services, corrections testing operations and related assets.

The acquisition gives Merck access to divesiran, an investigational small interfering RNA (siRNA) therapy for polycythemia vera (PV), a rare blood cancer characterised by excessive red blood cell production.

Vir could also receive up to US$45 million in near-term preclinical milestone payments and up to US$1.74 billion in potential development, regulatory, and commercial milestones.

The agreement also includes US$35 million in preclinical milestone payments, with additional development and commercial milestones bringing the total potential deal value to nearly US$1.2 billion.

Pfizer will assume responsibility for subsequent clinical development, manufacturing, regulatory submissions and commercialisation after the discovery phase.

The firm secured capital from a broad investor base, including medical institutions, pension funds, family offices, sovereign wealth funds and university endowments.

Under the agreement, AstraZeneca will pay US$40 million upfront, with an additional US$1.46 billion available in development and commercial milestone payments.

The launch expands Viome PRO’s clinical diagnostics offering, which also includes Gut Health PRO, Precision Health PRO, CancerDetect Oral & Throat and Oral Health PRO.

The project will replace existing buildings with new facilities designed to support clinical development, commercial production and advanced manufacturing technologies.